Search Results - Ivana Krajsová

  • Showing 1 - 10 results of 10
Refine Results
  1. 1
    Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma

    Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients w... by Paolo A. Ascierto, Reinhard Dummer, Helen Gogas, Keith T. Flaherty, Ana Arance, Mario Mandalà, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsová, Ralf Gutzmer, Jan Willem B. de Groot, Carmen Loquai, Ashwin Gollerkeri, Michael D. Pickard, Caroline Robert

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma

    Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastat... by Caroline Robert, Bogusława Karaszewska, Jacob Schachter, Piotr Rutkowski, Andrzej Maćkiewicz, Daniil Stroyakovskiy, Reinhard Dummer, Florent Grange, Laurent Mortier, Vanna Chiarion‐Sileni, Kamil Drucis, Ivana Krajsová, Axel Hauschild, Bijoyesh Mookerjee, Jeffery J. Legos, Y. Zhang, Stephen Lane, Dirk Schadendorf

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of <i>BRAF</i>-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial

    Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of <i>BRAF</i>-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial by Paolo A. Ascierto, Reinhard Dummer, Helen Gogas, Ana Arance, Mario Mandalà, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsová, Ralf Gutzmer, Vanna Chiarion‐Sileni, Caroline Dutriaux, Jan Willem B. de Groot, Naoya Yamazaki, Carmen Loquai, Caroline Robert, Keith T. Flaherty

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With<i>BRAF</i>V600–Mutant Melanoma

    COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With<i>BRAF</i>V600–Mutant Melanoma... by Reinhard Dummer, Keith T. Flaherty, Caroline Robert, Ana Arance, Jan Willem B. de Groot, Claus Garbe, Helen Gogas, Ralf Gutzmer, Ivana Krajsová, Gabriella Liszkay, Carmen Loquai, Mario Mandalà, Dirk Schadendorf, Naoya Yamazaki, Alessandra di Pietro, Jean Cantey-Kiser, Adrian Edwards, Paolo A. Ascierto

    Published 2022
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management

    Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management by Helen Gogas, Keith T. Flaherty, Reinhard Dummer, Paolo A. Ascierto, Ana Arance, Mario Mandalà, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsová, Ralf Gutzmer, Vanna Chiarion‐Sileni, Caroline Dutriaux, Jan Willem B. de Groot, Naoya Yamazaki, Carmen Loquai, Ashwin Gollerkeri, Michael D. Pickard, Caroline Robert

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma

    COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma by Dirk Schadendorf, Reinhard Dummer, Keith T Flaherty, Caroline Robert, Ana Arance, Jan Willem B. de Groot, Claus Garbe, Helen J Gogas, Ralf Gutzmer, Ivana Krajsová, Gabriella Liszkay, Carmen Loquai, Mario Mandalà, Naoya Yamazaki, Paola Queirolo, Carolin Guenzel, Anna Polli, Mahgull Thakur, Alessandra di Pietro, Paolo A Ascierto

    Published 2024
    Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

    Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial by Reinhard Dummer, Paolo A. Ascierto, Helen Gogas, Ana Arance, Mario Mandalà, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsová, Ralf Gutzmer, Vanna Chiarion‐Sileni, Caroline Dutriaux, Jan Willem B. de Groot, Naoya Yamazaki, Carmen Loquai, Laure A Moutouh-de Parseval, Michael D. Pickard, Victor Sandor, Caroline Robert, Keith T. Flaherty

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

    Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib by Caroline Robert, Bogusława Karaszewska, Jacob Schachter, Piotr Rutkowski, Andrzej Maćkiewicz, D. Stroiakovski, M. Lichinitser, Reinhard Dummer, Florent Grange, Laurent Mortier, Vanna Chiarion‐Sileni, Kamil Drucis, Ivana Krajsová, Axel Hauschild, Paul Lorigan, Pascal Wolter, Georgina V. Long, Keith T. Flaherty, Paul Nathan, Antoni Ribas, Anne-Marie Martin, Peng Sun, Wendy Crist, Jeff Legos, Stephen D. Rubin, Shonda M Little, Dirk Schadendorf

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments

    More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments by Lidija Kandolf Sekulović, Ketty Peris, Axel Hauschild, Alexander Stratigos, Jean‐Jacques Grob, Paul Nathan, Reinhard Dummer, Ana‐Maria Forsea, Christoph Höeller, Helen Gogas, Lev Demidov, Célèste Lebbé, C.U. Blank, Judit Oláh, Lars Bastholt, Davorin Herceg, Bart Neyns, Ricardo Vieira, Johan Hansson, Piotr Rutkowski, Ivana Krajsová, Matilda Bylaitė-Bučinskienė, Iris Zalaudek, Jasmina Marić-Brozić, Nada Babović, M. Banjin, Kadri Putnik, Georg Weinlich, Vladimir Todorović, K. Kirov, Janja Ocvirk, A. Zhukavets, M. Kukushkina, Luis de la Cruz‐Merino, Alketa Ymeri, Milan Risteski, Claus Garbe

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

    MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 tria... by Brigitte Dréno, John F Thompson, B. Mark Smithers, Mario Santinami, Thomas Jouary, Ralf Gutzmer, E. Levchenko, Piotr Rutkowski, Jean-Jacques Grob, S.I. Korovin, Kamil Drucis, Florent Grange, L. Machet, Peter Hersey, Ivana Krajsová, Alessandro Testori, Robert M. Conry, B. Guillot, Wim H.J. Kruit, Lev Demidov, John A. Thompson, Igor Bondarenko, Jarosław Jaroszek, Susana Puig, Gabriela Cinat, Axel Hauschild, Jelle J. Goeman, Hans C. van Houwelingen, Fernando Ulloa-Montoya, Andrea Callegaro, Benjamin Dizier, Bart Spiessens, Muriel Debois, Vincent Brichard, Jamila Louahed, Patrick Therasse, Channa Debruyne, John M. Kirkwood

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: